Biotech ETFs offer diversified exposure to multiple biotech stocks, reducing individual investment risk. Top biotech ETFs, like iShares and SPDR S&P, have large assets and low expense ratios.

BMO pointed to Gilead, Eli Lilly, Regeneron and Merck from the pharma world as names to watch for 2026. “With what felt like sector whiplash in 2025, we remain optimistic into 2026,” the team’s ...

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, ...

Traders should base analysis on the underlying index (XBI), as LABU's price action is distorted by leverage-induced drift.

The biotechnology sector has disappointed overall; we think there are better ways to get exposure to the healthcare sector. iShares Biotechnology ETF has underperformed relative to Health Care Select ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Insider got exclusive access to bankruptcy-risk ratings to identify vulnerable biotechs. The biotech market has dropped 42% this year, putting cash-starved or debt-laden firms at risk. The firm ...

TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...